Specifically, in pancreatic ductal adenocarcinoma, RSK2 expression is nearly three times higher than in normal tissues, resulting in a median survival decrease of 3.8 months and a hazard ratio of 1.28 (Supplemental Figure 1E). Here, RPS6KA3 is linked to pancreatic ductal adenocarcinoma.